Hypera S.A. (HYPE3.SA) stock analysis

In our weekly check, Hypera S.A. is graded B (A to F). Of 25 checks on debt, profit, cash flow and trend: 17 pass, warnings: 5, red flags: 3.

About Hypera S.A.

Hypera S.A. is a Healthcare company (Drug Manufacturers - Specialty & Generic) based in Brazil, listed on SAO as HYPE3.SA.

What our checks show for HYPE3.SA

Red flags

• The gross margin fell by 5.1 points, to 58.9%: costs are rising faster than prices.
• The stock has fallen as much as 75% from a peak. Would you have held through that?
• Recovering from its deepest fall took about 4.3 years.

Warning signs

• Operating profit covers interest only 2.5 times: a weak year could make the payments hard.
• The net margin fell by 2.3 points over 5 years, to 20.1%: the company keeps less of each sale as profit.
• Operating cash flow is only 0.78x net profit: part of the reported profit does not arrive as cash.
• The price swings a lot: 46.3% annual volatility. Expect large ups and downs.
• Return on capital (ROCE) is only 9.7%.

Strengths

• Analysts expect earnings per share to grow about 16% a year over the next years.
• The company keeps 20.1% of its revenue as net profit.
• Free cash flow is 11.1% of revenue: cash for dividends, buybacks or growth.
• The price is 7.9 times earnings (P/E), reasonable for its growth.
• Beta 0.11: the stock usually moves less than the market.
• Actively traded: about 4.1 million shares a day.

Similar companies

IPN.PA · ELAN · VTRS · 0867.HK · ALKS

Questions

What grade does Hypera S.A. (HYPE3.SA) have?

In our weekly check, Hypera S.A. is graded B (A to F). Of 25 checks on debt, profit, cash flow and trend: 17 pass, warnings: 5, red flags: 3. The grade is a risk check, not a buy or sell recommendation.

What are the main risks of HYPE3.SA stock?

This week's biggest flags for Hypera S.A.: Gross margin falling, Deep past fall, Slow recovery after falls. In total 8 of 25 checks show a warning or a red flag.

What does Hypera S.A. do?

Hypera S.A. is a Healthcare company (Drug Manufacturers - Specialty & Generic) based in Brazil, listed on SAO as HYPE3.SA.

The grade is a risk check, not a price forecast, and not investment advice. In our 10-year test (S&P 500, 2016-2026), stocks we graded A or B fell more than 30% 2-3 times less often than D or F, without a lower average return.

Updated 2026-10-31

Open the full analysis